FY2025 · ended Nov 30, 2025 · Revenue $31.57M, -1.3% YoY · Filed Feb 27, 2026
Cryo-Cell International, Inc. (CCEL) files with the SEC under industry code 8090, Services-Misc Health & Allied Services, NEC. In fiscal 2025, which ended Nov 30, 2025, it reported revenue of $31.6 million and a net loss of $2.4 million. Free cash flow was $5.2 million. As of Aug 31, 2026 it held $4.2 million in cash and investments and $8.8 million in total debt.
Revenue (TTM)
$31.13M
-2.0% vs year-ago TTM
Net income (TTM)
$-1.95M
-310.8% vs year-ago TTM
Operating cash flow (TTM)
$4.92M
-22.6% vs year-ago TTM
Free cash flow (TTM)
$4.65M
-24.8% vs year-ago TTM
EPS (TTM)
$-0.24
-316.4% vs year-ago TTM
Dividend per share
$0.25
-72.2% vs prior year
Shares outstanding
8.06M
-0.3% vs prior year
Net cash
$-4.59M
as of Aug 31, 2026
Operating margin
0.6%
FY 2026
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- CCEL (NYSE)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Oldsmar, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 862692
- Former names
- CRYO CELL INTERNATIONAL INC (until Oct 28, 2026)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Nov 30, 2025 |
FY 2024 Nov 30, 2024 |
FY 2023 Nov 30, 2023 |
FY 2022 Nov 30, 2022 |
FY 2021 Nov 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M |
| Operating income | $482,394 | $3.5M | -$12.3M | $4.0M | $4.0M |
| Net income | -$2.4M | $402,095 | -$9.5M | $2.8M | $2.1M |
| Diluted EPS | -$0.30 | $0.05 | -$1.14 | $0.33 | $0.25 |
| Operating cash flow | $5.5M | $6.0M | $8.9M | $8.6M | $7.9M |
| Free cash flow | $5.2M | $3.6M | $2.1M | -$3.6M | $6.1M |
| Total assets | $61.7M | $64.7M | $61.2M | $64.9M | $60.7M |
| Total liabilities | $80.3M | $77.9M | $72.3M | $66.4M | $56.5M |
| Stockholders' equity | -$18.6M | -$13.2M | -$11.0M | -$1.5M | $4.2M |
| Cash and investments | $3.3M | $3.5M | $980,250 | $1.7M | $8.3M |
| Total debt | $9.3M | $9.4M | $9.7M | $9.3M | $2.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 28, 2026 | Oct 27, 2026 |
| ARS | Annual report to shareholders | Oct 13, 2026 | Nov 30, 2025 |
| 10-Q | Quarterly report | Oct 9, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Jul 15, 2026 | May 31, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
May 8, 2026 | May 6, 2026 |
All 908 Cryo-Cell International, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.